TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens.
TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens.
复制标题
DOI：
10.1007/978-1-4939-0345-0_27
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Klinman DM
中科院分区：
文献类型：
--
作者：
Shirota H;Klinman DM
癌症疫苗的主要目标是诱导肿瘤特异性细胞毒性T淋巴细胞（CTL），能够根除已建立的肿瘤并预防/根除其转移性扩散。CpG寡核苷酸（CpG ODN）激活并支持免疫细胞的成熟，包括浆细胞样树突状细胞和B淋巴细胞，这些细胞表达toll样受体9 （TLR9）并能够将肿瘤抗原呈递给T细胞。因此，CpG ODN是有效的疫苗佐剂。CpG ODN的佐剂活性通过保持它们与共同施用的疫苗抗原在物理和时间上的密切接近而得到改善。本工作描述了一种将CpG ODN化学偶联到抗原和/或癌细胞上的方法，从而改善了CTL反应。
The primary goal of cancer vaccines is to elicit tumor-specific cytotoxic T lymphocytes (CTL) capable of eradicating established tumors and preventing/eradicating their metastatic spread. CpG oligonucleotides (CpG ODN) activate and support the maturation of immune cells, including plasmacytoid dendritic cells and B lymphocytes, that express Toll-like receptor 9 (TLR9) and are capable of presenting tumor antigens to T cells. Thus, CpG ODN are effective vaccine adjuvants. The adjuvant activity of CpG ODN is improved by maintaining them in close physical and temporal proximity to the co-administered vaccine antigen. This work describes a method of chemically conjugating CpG ODN to antigens and/or cancer cells that improve the resulting CTL response.